

Specialty Guideline Management

Aldurazyme

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Aldurazyme	laronidase

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹

Aldurazyme is indicated for the treatment of adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms.

Limitations of Use

- The safety and effectiveness of treating mildly affected patients with the Scheie form have not been established.
- The effect of Aldurazyme on central nervous system manifestations of the disorder has not been determined.

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

Initial Requests:

- Alpha-L-iduronidase enzyme assay or genetic testing results supporting diagnosis.
- Chart notes or medical records documenting clinical signs and symptoms of disease at baseline (e.g., coarse facial features, frequent upper respiratory infections, inguinal or umbilical hernia, hepatosplenomegaly, characteristic skeletal findings, noninflammatory arthropathy, corneal clouding, hydrocephalus, developmental delay).

Continuation Requests:

- Chart notes or medical records documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression (e.g., improvement, stabilization, or slowing of disease progression for forced vital capacity, 6-minute walk test, apnea/hypoapnea index (AHI), liver volume, active joint range of motion, urinary glycosaminoglycan (GAG) levels).

Prescriber Specialties

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

Coverage Criteria

Mucopolysaccharidosis I (MPS I)¹⁻⁴

Authorization of 12 months may be granted for treatment of MPS I when all of the following criteria are met:

- Diagnosis of MPS I was confirmed by enzyme assay demonstrating a deficiency of alpha-L-iduronidase enzyme activity or by genetic testing.
- Member has one of the following:
 - The Hurler form (i.e., severe MPS I).
 - The Hurler-Scheie form (i.e., attenuated MPS I).
 - The Scheie form (Scheie syndrome; i.e., attenuated MPS I) with moderate to severe symptoms (e.g., normal intelligence, less progressive physical problems, corneal clouding, joint stiffness, valvular heart disease).

Reference number(s)
2049-A

- Member exhibits clinical signs and symptoms of disease at baseline (e.g., coarse facial features, frequent upper respiratory infections, inguinal or umbilical hernia, hepatosplenomegaly, characteristic skeletal findings, noninflammatory arthropathy, corneal clouding, hydrocephalus, developmental delay).

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the Coverage Criteria section who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression (e.g., improvement, stabilization, or slowing of disease progression in forced vital capacity, 6-minute walk test, apnea/hypopnea index (AHI), liver volume, active joint range of motion, urinary glycosaminoglycan (GAG) levels).

References

1. Aldurazyme [package insert]. Cambridge, MA: Genzyme Corporation; December 2023.
2. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). *J Pediatr*. 2004;144:581-588.
3. Muenzer J, Wraith JE, Clarke LA; International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. *Pediatrics*. 2009 Jan;123(1):19-29.
4. Clarke LA. Mucopolysaccharidosis Type I. 2002 Oct 31 [Updated 2025 Dec 4]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Accessed Jan 13, 2025.